Bioventus Inc. (NYSE:BVS - Get Free Report) SVP Anthony D'adamio sold 3,054 shares of Bioventus stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $4.75, for a total value of $14,506.50. Following the completion of the transaction, the senior vice president now owns 58,242 shares in the company, valued at $276,649.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Anthony D'adamio also recently made the following trade(s):
- On Friday, March 15th, Anthony D'adamio sold 3,125 shares of Bioventus stock. The shares were sold at an average price of $5.46, for a total value of $17,062.50.
Bioventus Stock Up 1.3 %
Shares of BVS stock opened at $4.63 on Tuesday. Bioventus Inc. has a 1-year low of $0.86 and a 1-year high of $6.08. The stock's fifty day moving average price is $4.96 and its 200 day moving average price is $4.47. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.53 and a quick ratio of 1.01. The company has a market cap of $366.56 million, a price-to-earnings ratio of -1.84 and a beta of 0.50.
Bioventus (NYSE:BVS - Get Free Report) last announced its earnings results on Tuesday, March 12th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.01. Bioventus had a positive return on equity of 2.25% and a negative net margin of 30.49%. The firm had revenue of $135.42 million for the quarter, compared to the consensus estimate of $124.84 million. On average, research analysts expect that Bioventus Inc. will post 0.16 earnings per share for the current fiscal year.
Institutional Trading of Bioventus
Protect Your Bank Account Before It’s Too Late
From Weiss Ratings | Ad
For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account.
It gives them the power to monitor every single transaction …
Stop right now and do these 3 things to protect yourself
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LPL Financial LLC acquired a new stake in Bioventus during the 4th quarter worth about $26,000. PNC Financial Services Group Inc. lifted its position in Bioventus by 1,845.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company's stock worth $30,000 after acquiring an additional 2,030 shares during the period. UBS Group AG lifted its position in Bioventus by 72.9% during the 4th quarter. UBS Group AG now owns 12,744 shares of the company's stock worth $33,000 after acquiring an additional 5,372 shares during the period. Delphia USA Inc. acquired a new stake in Bioventus during the 4th quarter worth about $33,000. Finally, XTX Topco Ltd acquired a new stake in Bioventus during the 2nd quarter worth about $35,000. Institutional investors and hedge funds own 62.94% of the company's stock.
Analyst Upgrades and Downgrades
Separately, Craig Hallum boosted their target price on Bioventus from $6.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, March 13th.
Get Our Latest Report on Bioventus
About Bioventus
(
Get Free Report)
Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
